<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 10.2: Advanced Lipid Panels and Cardiovascular Risk Markers</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - RED/MAROON theme for Cardiovascular Health */
        .module-header {
            background: linear-gradient(135deg, #991b1b 0%, #dc2626 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #991b1b;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #991b1b;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #991b1b;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #fef2f2;
            border: 2px solid #dc2626;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #991b1b;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #991b1b;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #dc2626;
        }

        .term-item .term {
            font-weight: 700;
            color: #991b1b;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #991b1b;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #ffcfcf 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Welcome/Intro Box */
        .welcome-box {
            background: linear-gradient(135deg, #fef2f2 0%, #fff1f1 100%);
            padding: 30px 35px;
            border-radius: 14px;
            margin-bottom: 40px;
            border: 1px solid #fecaca;
        }

        .welcome-box h3 {
            margin: 0 0 15px 0;
            font-size: 20px;
            color: #991b1b;
            font-weight: 600;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #991b1b 0%, #dc2626 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #dc2626, #991b1b);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #991b1b 0%, #dc2626 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Comparison Table Styling */
        .data-table-container {
            overflow-x: auto;
            margin: 30px 0;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background-color: #f9fafb;
            padding: 15px;
            font-weight: 600;
            color: #991b1b;
            border-bottom: 2px solid #e5e7eb;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #e5e7eb;
            color: #4b5563;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .check-understanding .box-label {
            font-weight: 600;
            color: #8B6914;
            margin: 0 0 8px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .reveal-btn {
            background: #991b1b;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            font-family: inherit;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #991b1b;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #fff1f1;
            border-radius: 8px;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: linear-gradient(135deg, #f5f5f5 0%, #e8e8e8 100%);
            padding: 22px 25px;
            margin-top: 35px;
            border-radius: 8px;
            border: 1px solid #ddd;
        }

        .references-box {
            margin-top: 40px;
            padding: 25px;
            background: #f9fafb;
            border-radius: 12px;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            color: #333;
            margin-top: 0;
        }

        .references-box ul {
            padding-left: 20px;
        }

        .references-box li {
            margin-bottom: 8px;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            height: auto;
            margin-bottom: 15px;
            opacity: 0.9;
        }

        .lesson-footer .brand {
            color: #991b1b;
            font-weight: 600;
            margin: 0;
            font-size: 15px;
        }

        .lesson-footer .copyright {
            color: #888;
            font-size: 13px;
            margin: 10px 0 0 0;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 10: Cardiovascular and Metabolic Health</p>
            <h1 class="lesson-title">Lesson 10.2: Advanced Lipid Panels and Cardiovascular Risk Markers</h1>
            <div class="lesson-meta">
                <span class="meta-item">32 min read</span>
                <span class="meta-item">Lesson 2 of 10</span>
            </div>
        </header>

        <!-- Table of Contents -->
        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Failure of LDL-C Alone</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Apolipoprotein B (ApoB)</a></li>
                <li><a href="#section3"><span class="section-num">3</span>LDL Particle Size and Density</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Lipoprotein(a): Genetic Risk</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Vascular Inflammatory Markers</a></li>
                <li><a href="#section6"><span class="section-num">6</span>The ALIGN Method Application</a></li>
            </ul>
        </div>

        <!-- Learning Objectives -->
        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Explain the concept of "lipid discordance" and why LDL cholesterol mass is an incomplete risk marker.</li>
                <li>Identify Apolipoprotein B (ApoB) as the primary driver of atherogenesis and interpret its clinical ranges.</li>
                <li>Differentiate between Pattern A and Pattern B LDL and their respective impacts on vascular health.</li>
                <li>Assess the significance of Lipoprotein(a) and vascular inflammatory markers like hs-CRP and Lp-PLA2.</li>
                <li>Utilize advanced lab data to personalize interventions using the ALIGN Methodâ„¢.</li>
            </ul>
        </div>

        <!-- Welcome Box -->
        <div class="welcome-box">
            <h3>Beyond the Standard Lipid Panel</h3>
            <p>For decades, the "Standard Lipid Panel"â€”Total Cholesterol, LDL, HDL, and Triglyceridesâ€”has been the gold standard for assessing cardiovascular risk. However, modern research reveals that <span class="highlight">nearly 50% of patients hospitalized for a first heart attack have "normal" LDL-C levels</span>. As an Integrative Health Coach, relying on outdated metrics leaves your clients vulnerable. This lesson equips you with the expertise to interpret advanced lipoproteomics, allowing you to identify hidden risks and leverage functional interventions before a clinical event occurs.</p>
        </div>

        <!-- Key Terms -->
        <div class="key-terms-box">
            <p class="box-label">ðŸ”¬ Key Cardiovascular Terms</p>
            <div class="terms-grid">
                <div class="term-item">
                    <p class="term">Apolipoprotein B (ApoB)</p>
                    <p class="definition">The primary structural protein found on all potentially atherogenic (plaque-forming) particles, including LDL, VLDL, and IDL.</p>
                </div>
                <div class="term-item">
                    <p class="term">Discordance</p>
                    <p class="definition">A clinical scenario where the concentration of cholesterol (LDL-C) does not match the concentration of particles (LDL-P or ApoB).</p>
                </div>
                <div class="term-item">
                    <p class="term">Lp-PLA2 (PLAC Test)</p>
                    <p class="definition">An enzyme marker specific to vascular inflammation; high levels indicate that plaque is actively becoming unstable and prone to rupture.</p>
                </div>
                <div class="term-item">
                    <p class="term">sdLDL</p>
                    <p class="definition">Small dense Low-Density Lipoprotein; these particles are more likely to enter the arterial wall and oxidize, making them highly atherogenic.</p>
                </div>
            </div>
        </div>

        <h2 id="section1">The Failure of LDL-C Alone</h2>
        <p>LDL Cholesterol (LDL-C) measures the <span class="highlight">mass</span> of cholesterol contained within LDL particles. While useful, it is essentially like measuring the total weight of cargo in a fleet of trucks rather than counting the number of trucks on the road. In cardiovascular disease, the number of "trucks" (particles) is a much stronger predictor of risk than the weight of the "cargo" (cholesterol).</p>

        <p>A 2021 study involving over 300,000 individuals found that when LDL-C and ApoB are discordant, the risk of cardiovascular events tracks with ApoB, not LDL-C. This means a client with a "low" LDL of 70 mg/dL but a "high" ApoB of 110 mg/dL remains at high risk for atherosclerosis. This phenomenon is common in individuals with metabolic syndrome, insulin resistance, and type 2 diabetes.</p>

        <!-- Statistics Box -->
        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">50%</div>
                    <div class="stat-label">MI Patients with Normal LDL</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">25%</div>
                    <div class="stat-label">Population with Discordance</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">3.5x</div>
                    <div class="stat-label">Risk Increase with sdLDL</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">1 in 5</div>
                    <div class="stat-label">Have Elevated Lp(a)</div>
                </div>
            </div>
        </div>

        <h2 id="section2">Apolipoprotein B (ApoB): The Master Marker</h2>
        <p>ApoB is arguably the most important marker in a modern cardiovascular assessment. Every atherogenic lipoproteinâ€”whether it is VLDL, IDL, or LDLâ€”contains exactly <span class="highlight">one molecule of ApoB</span>. Therefore, measuring ApoB provides a precise count of the total number of particles that can contribute to arterial plaque.</p>

        <p>The mechanism is simple: the more ApoB-containing particles in circulation, the higher the probability that one will cross the endothelial barrier, become trapped in the sub-endothelial space, and initiate the inflammatory cascade that leads to plaque. Expert consensus (including the 2019 ESC/EAS guidelines) now suggests that ApoB is a more accurate risk marker than LDL-C, especially in those with high triglycerides or obesity.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Risk Category</th>
                        <th>ApoB Level (mg/dL)</th>
                        <th>Clinical Significance</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Optimal</td>
                        <td>&lt; 60</td>
                        <td>Extremely low risk; comparable to hunter-gatherer populations.</td>
                    </tr>
                    <tr>
                        <td>Moderate Risk</td>
                        <td>80 - 100</td>
                        <td>Standard "average" risk; requires lifestyle monitoring.</td>
                    </tr>
                    <tr>
                        <td>High Risk</td>
                        <td>100 - 130</td>
                        <td>Increased particle count; likely insulin resistance present.</td>
                    </tr>
                    <tr>
                        <td>Very High Risk</td>
                        <td>&gt; 130</td>
                        <td>Aggressive plaque formation likely; immediate intervention needed.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section3">LDL Particle Size and Density</h2>
        <p>Not all LDL particles are created equal. Advanced testing like the <span class="highlight">NMR LipoProfile</span> allows us to see the distribution of particle sizes. We generally categorize these into two patterns:</p>
        
        <ul>
            <li><strong>Pattern A:</strong> Large, buoyant LDL particles. These are less likely to penetrate the arterial wall and are considered less atherogenic.</li>
            <li><strong>Pattern B:</strong> Small, dense LDL (sdLDL) particles. These are dangerous because they easily slip through the endothelium, have a higher affinity for arterial proteoglycans, and are more susceptible to oxidation.</li>
        </ul>

        <p>Pattern B is often driven by <span class="highlight">hypertriglyceridemia</span> and low HDL, a triad known as the "Atherogenic Dyslipidemia Complex." When you see high triglycerides (>150 mg/dL), you can almost guarantee the presence of small dense LDL, even if the total LDL-C looks normal.</p>

        <h2 id="section4">Lipoprotein(a): The Genetic Wildcard</h2>
        <p>Lipoprotein(a), or Lp(a), is a standard LDL particle with an additional protein called apolipoprotein(a) attached via a disulfide bridge. Unlike other lipids, Lp(a) levels are <span class="highlight">90% genetically determined</span> and are largely unaffected by diet or typical exercise routines.</p>
        
        <p>Lp(a) is particularly dangerous because it is both pro-atherogenic (like LDL) and pro-thrombotic (it mimics plasminogen, potentially interfering with the body's ability to dissolve blood clots). A 2018 meta-analysis confirmed that individuals with Lp(a) levels above 50 mg/dL (or 125 nmol/L) have a significantly higher risk of myocardial infarction and aortic stenosis, regardless of their other lipid levels.</p>

        <!-- Case Study -->
        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: Hidden Risk in "Healthy" Profiles</p>
                    <p style="color: rgba(255,255,255,0.8); font-size: 13px; margin: 0;">The ALIGN Method in Action</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">M</div>
                    <div class="patient-info">
                        <h4>Marcus, 52</h4>
                        <p>Triathlete, low-fat diet, BMI 23. Standard LDL: 105 mg/dL.</p>
                    </div>
                </div>
                <p><strong>The Challenge:</strong> Marcus was frustrated by a "calcium score" (CAC) of 150 despite having "perfect" lipids according to his primary physician. He felt his healthy lifestyle was failing him.</p>
                <p><strong>Advanced Assessment (A - Assess Bio-Individuality):</strong> We ran an advanced panel. Results: ApoB 128 mg/dL (High), Lp(a) 85 mg/dL (High), and Pattern B LDL.</p>
                <p><strong>Intervention (I - Integrate Multimodal):</strong> Because Marcus was a triathlete, his high-carb/low-fat diet was driving up his triglycerides and sdLDL. We shifted him to a higher-fiber, moderate-fat diet and introduced 4g of high-quality EPA/DHA to address particle density.</p>
                <p><strong>Outcome:</strong> Six months later, his ApoB dropped to 85 mg/dL, and his LDL shifted to Pattern A. While his Lp(a) remained high (genetic), his overall particle count and inflammatory burden were significantly reduced, stabilizing his risk profile.</p>
            </div>
        </div>

        <h2 id="section5">Vascular Inflammatory Markers</h2>
        <p>Lipids provide the "fuel" for the fire, but inflammation is the "match." To truly assess risk, we must look at how the immune system is interacting with the vasculature.</p>
        
        <p><strong>1. hs-CRP (High-Sensitivity C-Reactive Protein):</strong> A systemic marker of inflammation. Levels >3.0 mg/L indicate high cardiovascular risk. The JUPITER trial demonstrated that lowering CRP can reduce heart attack risk even in those with low LDL.</p>
        
        <p><strong>2. Lp-PLA2 (PLAC Test):</strong> Unlike CRP, which can be elevated by a stubbed toe or a cold, Lp-PLA2 is specific to the <span class="highlight">arterial wall</span>. It measures the activity of an enzyme that breaks down oxidized LDL within a plaque. High levels suggest that the plaque is "soft" and prone to rupture.</p>

        <h2 id="section6">The ALIGN Methodâ„¢ Application</h2>
        <p>Applying the ALIGN Methodâ„¢ to cardiovascular health shifts the focus from symptom suppression to systemic resilience:</p>
        
        <div class="principle-card">
            <p class="principle-title">Assess Bio-Individuality (A)</p>
            <p class="principle-text">Move beyond the standard panel. Order ApoB, Lp(a), and an NMR LipoProfile for every client with a family history or metabolic concerns.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">Leverage Functional Systems (L)</p>
            <p class="principle-text">Recognize that gut health (TMAO production) and oral health (periodontal bacteria) directly influence vascular inflammation markers like hs-CRP.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">Integrate Multimodal Interventions (I)</p>
            <p class="principle-text">Use targeted nutrients like Amla, Bergamot, or high-dose Omega-3s based on whether the issue is particle count (ApoB) or particle size (sdLDL).</p>
        </div>

        <!-- Check Your Understanding -->
        <div class="check-understanding">
            <p class="box-label">Knowledge Check</p>
            <p class="box-subtitle">Test your grasp of advanced lipid markers.</p>

            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">Why is ApoB considered a superior marker to LDL-C for predicting cardiovascular risk?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">ApoB measures the total number of atherogenic particles (one ApoB per particle), whereas LDL-C only measures the mass of cholesterol. Risk is driven by particle count, as more particles increase the probability of arterial wall penetration.</div>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">A client has an LDL-C of 90 mg/dL but Triglycerides of 210 mg/dL. What is the likely LDL pattern?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">The likely pattern is Pattern B (small, dense LDL). High triglycerides drive the remodeling of LDL particles into smaller, denser, and more atherogenic versions.</div>
            </div>
        </div>

        <!-- Key Takeaways -->
        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><strong>LDL-C is incomplete:</strong> Always look for discordance between cholesterol mass and particle count.</li>
                <li><strong>ApoB is the primary driver:</strong> Aim for ApoB < 80 mg/dL for primary prevention and < 60 mg/dL for high-risk individuals.</li>
                <li><strong>Check Lp(a) once:</strong> It is a genetic risk factor that identifies "hidden" risk in seemingly healthy individuals.</li>
                <li><strong>Inflammation matters:</strong> Use hs-CRP and Lp-PLA2 to determine if the lipids in circulation are actually causing vascular damage.</li>
                <li><strong>Personalize via ALIGN:</strong> Tailor dietary and supplement interventions to the specific lipid sub-fractions identified.</li>
            </ul>
        </div>

        <!-- References -->
        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Sniderman, A. D., et al. (2019). "Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review." <em>JAMA Cardiology</em>.</li>
                <li>Tsimikas, S. (2017). "A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, and Treatment." <em>Journal of the American College of Cardiology</em>.</li>
                <li>Ridker, P. M. (2018). "Clinician's Guide to Reducing Inflammation to Prevent Cardiovascular Disease." <em>Circulation</em>.</li>
                <li>Cromwell, W. C., et al. (2007). "LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study." <em>Journal of Clinical Lipidology</em>.</li>
                <li>Grundy, S. M., et al. (2019). "AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol." <em>Circulation</em>.</li>
                <li>Boren, J., et al. (2020). "Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights." <em>European Heart Journal</em>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy Certified Integrative Health Coach</p>
            <p class="copyright">&copy; 2024 AccrediPro Academy. All rights reserved. Advanced Cardiovascular Specialist Track.</p>
        </footer>
    </div>
</body>

</html>